VB-111 for cancer

Expert Opinion on Biological Therapy

Volumn 11, Issue 12, 2011, Pages 1669-1676

  Triozzi, Pierre L ^a   Borden, Ernest C ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

adenovirus; angiogenesis inhibitor; Fas; tumor necrosis factor; vascular disrupting agent

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VB 111;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; METASTASIS; NEUROENDOCRINE TUMOR; NONHUMAN; SOLID TUMOR; THYROID CARCINOMA; TUMOR VASCULARIZATION;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD95; APOPTOSIS; ENDOTHELIN-1; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROMOTER REGIONS, GENETIC; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TREATMENT OUTCOME;

ADENOVIRIDAE;

EID: 80555127380     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.618122     Document Type: Article

References (32)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6
2. Horsman MR, Bohn AB, Busk M. Vascular targeting therapy: potential benefit depends on tumor and host related effects. Exp Oncol 2010;11:143-8
3. Bergers G, Hanahan D. Modes of resistance to anti-ngiogenic therapy. Nat Rev Cancer 2008;8:592-603
4. Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies, J Clin Oncol. 2002;20:3906-27
5. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2:689-92
6. Sedlacek HH. Pharmacological aspects of targeting cancer gene therapy to endothelial cells. Crit Rev Oncol Hematol 2001;37:169-215
7. Kong HL, Crystal RG. Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst 1998;90:273-86
8. Persano L, Crescenzi M, Indraccolo S. Anti-angiogenic gene therapy of cancer: current status and future prospects. Mol Aspects Med 2007;28:87-114
9. Hedman M, Hartikainen J, Syvanne M, et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT).Circulation 2003;107:2677-83
10. Makinen K, Manninen H, Hedman M, et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded Phase II study. Mol Ther 2002;6:127-33
11. Li HL, Li S, Shao JY, et al. Pharmacokinetic and pharmacodynamic study of intratumoral injection of an adenovirus encoding endostatin in patients with advanced tumors. Gene Ther 2008;15:247-56
12. Cunningham CC, Chada S, Merritt JA, et al. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a Phase I study. Mol Ther 2005;11:149-59
13. Triozzi PL, Allen KO, Carlisle RR, et al. Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma. Clin Cancer Res 2005;11:4168-75
14. Harats D, Kurihara H, Belloni P, et al. Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter. J Clin Invest 1995;95:1335-44
15. Greenberger S, Shaish A, Varda-Bloom N, et al. Transcription-controlled gene therapy against tumor angiogenesis. J Clin Invest 2004;113:1017-24
16. Boldin MP, Mett IL, Varfolomeev EE, et al. Self-association of the "death domains" of the p55 tumor necrosis factor (TNF) receptor and Fas/ APO1 prompts signaling for TNF and Fas/APO1 effects. J Biol Chem 1995;270:387-91
17. Marsden PA, Brenner BM. Transcriptional regulation of the endothelin-1 gene by TNF-alpha. Am J Physiol 1992;262:C854-61
18. Varda-Bloom N, Shaish A, Gonen A, et al. Tissue-specific gene therapy directed to tumor angiogenesis. Gene Ther 2001;8:819-27
19. Brenner AJ, Rogge J, Cohen Y, et al. Antiangiogenic gene therapy with VB111 is active in glioblastoma xenografts. [abstract 5400]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 April 2-6; Orlando, Florida. Philadelphia (PA): AACR; 2011
20. Peled M, Shaish A, Greenberger S, et al. Antiangiogenic systemic gene therapy combined with doxorubicin administration induced caspase 8 and 9-mediated apoptosis in endothelial cells and an anti-metastasis effect. Cancer Gene Ther 2008;15:535-42
21. Breitbart E, Cohen YC, Bangio L. VB-111 a novel anti-angiogenic vector and a promising treatment for metastatic cancer in combination with other anticancer drugs. [abstract 3283]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 April 2-6; Orlando, Florida. Philadelphia (PA): AACR; 2011
22. Breitbart E, Bangio L, Harats D, et al. A novel anti-angiogenic vector with vascular disrupting activity as a promising treatment for metastatic cancer. [abstract 1369]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; 2010
23. Triozzi P, Brenner A, Giles F, et al. A Phase I trial of VB-111, a tissue and condition specific vascular disruptive anti-angiogenic agent, based on novel Vascular Targeting System, VTS, for treatment of patients with advanced metastatic cancer. [abstract 1361]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; 2010
24. Vascular Biogenics Ltd operating as VBL therapeutics. Safety and efficacy of VB-111 in subjects with advanced differentiated thyroid cancer. ClinicalTrials.gov: NCT01229865 Available from: http://clinicaltrials.gov/ct2/ show/NCT01229865? term=NCT01229865&rank=1
25. Vascular Biogenics Ltd operating as VBL therapeutics. Single-arm open-label multicenter study of VB-111 in patients with recurrent glioblastoma multiforme. ClinicalTrials.gov: NCT01260506 Available from: http:// clinicaltrials.gov/ct2/show/NCT01260506? term=NCT01260506&rank=1
26. Varda-Bloom N, Hodish I, Shaish A, et al. Specific induction of tumor neovasculature death by modified murine PPE-1 promoter armed with HSV-TK. Pathobiology 2008;75:346-55
27. Hodish I, Tal R, Shaish A, et al. Systemic administration of radiation-potentiated anti-angiogenic gene therapy against primary and metastatic cancer based on transcriptionally controlled HSV-TK. Cancer Biol Ther 2009;8:424-32
28. Peled M, Shaish A, Katav A, et al. Systemic administration of a conditionally replicating adenovirus, targeted to angiogenesis, reduced lung metastases burden in cotton rats. Clin Cancer Res 2009;15:1664-73
29. Levanon K, Varda-Bloom N, Greenberger S, et al. Vascular wall maturation and prolonged angiogenic effect by endothelial-specific plateletderived growth factor expression. Pathobiology 2006;73:149-58
30. Tal R, Shaish A, Rofe K, et al. Endothelial-targeted gene transfer of hypoxia-inducible factor-1alpha augments ischemic neovascularization following systemic administration. Mol Ther 2008;16:1927-36
31. Nemunaitis J, Cunningham C, Buchanan A, et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 2001;8:746-59
32. Rini BI, Garcia JA, Cooney MM, et al. A Phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res 2009;15:6277-83